UY34008A - ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. - Google Patents
?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.Info
- Publication number
- UY34008A UY34008A UY0001034008A UY34008A UY34008A UY 34008 A UY34008 A UY 34008A UY 0001034008 A UY0001034008 A UY 0001034008A UY 34008 A UY34008 A UY 34008A UY 34008 A UY34008 A UY 34008A
- Authority
- UY
- Uruguay
- Prior art keywords
- forms
- prepare
- processes
- pharmaceutical composition
- solid state
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a nuevas formas cristalinas de ácido (2S)?2?ter?butoxi?2?(4?(2,3?dihidropirano[4,3,2?de]quinolin?7?il)?2?metilquinolin?3?il)acético, su sal clorhidrato, nuevas formas cristalinas de la sal clorhidrato, sus métodos de preparación, sus composiciones farmacéuticas y su uso en el tratamiento de infección por virus de inmunodeficiencia humana (HIV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471655P | 2011-04-04 | 2011-04-04 | |
US201161481908P | 2011-05-03 | 2011-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34008A true UY34008A (es) | 2012-11-30 |
Family
ID=45992855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034008A UY34008A (es) | 2011-04-04 | 2012-04-09 | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140094486A1 (es) |
EP (1) | EP2694160A1 (es) |
JP (1) | JP2014510139A (es) |
AR (1) | AR085856A1 (es) |
AU (1) | AU2012240313A1 (es) |
CA (1) | CA2830845A1 (es) |
TW (1) | TW201302761A (es) |
UY (1) | UY34008A (es) |
WO (1) | WO2012138669A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
EA201291301A1 (ru) | 2010-07-02 | 2013-05-30 | Джилид Сайэнс, Инк. | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич |
WO2012138670A1 (en) * | 2011-04-04 | 2012-10-11 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
EA024952B1 (ru) | 2011-04-21 | 2016-11-30 | Джилид Сайэнс, Инк. | Бензотиазолы и их применение для лечения вич-инфекции |
US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
RU2014115227A (ru) | 2012-04-20 | 2015-10-27 | Джилид Сайэнс, Инк. | Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции |
WO2014055618A1 (en) * | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
CN118477088A (zh) | 2017-12-07 | 2024-08-13 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
CN111333667B (zh) * | 2020-04-14 | 2021-04-27 | 浙江工业大学 | 一种含硒杂环的萘酰亚胺类衍生物及其制备方法和抗病毒应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0649651B1 (en) | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
-
2012
- 2012-04-03 JP JP2014503916A patent/JP2014510139A/ja active Pending
- 2012-04-03 AU AU2012240313A patent/AU2012240313A1/en not_active Abandoned
- 2012-04-03 CA CA2830845A patent/CA2830845A1/en not_active Abandoned
- 2012-04-03 WO PCT/US2012/032026 patent/WO2012138669A1/en active Application Filing
- 2012-04-03 EP EP12715787.3A patent/EP2694160A1/en not_active Withdrawn
- 2012-04-03 TW TW101111886A patent/TW201302761A/zh unknown
- 2012-04-04 AR ARP120101176A patent/AR085856A1/es not_active Application Discontinuation
- 2012-04-09 UY UY0001034008A patent/UY34008A/es not_active Application Discontinuation
-
2013
- 2013-10-03 US US14/045,037 patent/US20140094486A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012240313A1 (en) | 2013-05-02 |
AR085856A1 (es) | 2013-10-30 |
CA2830845A1 (en) | 2012-10-11 |
WO2012138669A1 (en) | 2012-10-11 |
EP2694160A1 (en) | 2014-02-12 |
TW201302761A (zh) | 2013-01-16 |
US20140094486A1 (en) | 2014-04-03 |
JP2014510139A (ja) | 2014-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2015002335A1 (es) | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
CL2015002860A1 (es) | Antagonistas de la alfa-v-beta-6 integrina | |
CL2015001055A1 (es) | Composiciones para lavado de ropa; y uso de dicha composicion. | |
TR201911140T4 (tr) | Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları. | |
BR112014031262A2 (pt) | composições biocatalisadoras inovadoras e processos para uso. | |
CO6771428A2 (es) | Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales | |
TR201909788T4 (tr) | C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
BR112014000236A2 (pt) | lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas | |
UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
GT201400017A (es) | Derivados de piridin-2 (1h) -ona como inhibidores de jak | |
SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
BR112014025416A2 (pt) | AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201019 |